论文部分内容阅读
目的:探讨小剂量Acla+Ara-C+G-CSF联合应用,即AcAG方案治疗急性髓系白血病的临床效果。方法:Acla 7 mg/m2静脉注射,1次/ d,第1天~第7天;Ara-C 10 mg/m2,肌肉注射,1次/ 12 h,第1天~第14天;G-CSF 100 μg/m2皮下注射,1次/ d,第1天~第14天。4周为1周期。共治疗急性髓系白血病患者8例,其中4例系由MDS转为AML。2例经其他方案治疗未缓解或复发后改为该方案治疗。结果:3周期治疗后,5例CR,1例PR,2例NR。完全缓解率62.5 %,总有效率75 %。全组均未见严重毒副反应。结论:AcAG方案是治疗急性髓系白血病的可靠方法,对原发性、复发性及经其他方案治疗无效的AML患者均有较好疗效。
Objective: To investigate the combination of low dose Acla + Ara-C + G-CSF, which is the clinical effect of AcAG regimen in the treatment of acute myeloid leukemia. Methods: Acla 7 mg / m2 was given intravenously once a day for the first day to the seventh day; Ara-C 10 mg / m2 was intramuscularly injected once a day for 12 hours; the first day to the fourteenth day; CSF 100 μg / m2 subcutaneously, once daily, day 1 to day 14. 4 weeks for a cycle. A total of 8 cases of acute myeloid leukemia patients, including 4 cases of MDS converted to AML. 2 cases of other programs did not alleviate the treatment or relapse to the program after treatment. Results: After 3 cycles of treatment, 5 cases of CR, 1 case of PR, 2 cases of NR. Complete remission rate of 62.5%, the total effective rate of 75%. The whole group were no serious side effects. CONCLUSIONS: The AcAG regimen is a reliable method of treating acute myeloid leukemia with good efficacy in patients with primary, recurrent, and ineffective AML.